» Articles » PMID: 32962686

Identification of an Alternative Splicing Signature As an Independent Factor in Colon Cancer

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2020 Sep 23
PMID 32962686
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Colon cancer is a common malignant tumor with a poor prognosis. Abnormal alternative splicing (AS) events played a part in the occurrence and metastasis of the tumor. We aimed to develop a survival-associated AS signature in colon cancer.

Methods: The Percent Spliced In values of AS events were available in The Cancer Genome Atlas (TCGA) SpliceSeq database. Univariate Cox analysis was carried out to detect the prognosis-related AS events. We created a predictive model on account of the survival-associated AS events, which was further validated with a training-testing group design. Kaplan-Meier analysis was applied to assess patient survival. The area under curve (AUC) of receiver operating characteristic (ROC) was performed to evaluate the predictive values of this model. Meanwhile, the clinical relevance of the signature and its regulatory relationship with splicing factors (SFs) were also evaluated.

Results: In total, 2132 survival-related AS events were identified from colon cancer samples. We developed an eleven-AS signature, in which the 5-year AUC value was 0.911. Meanwhile, the AUC values at five years were 0.782 and 0.855 in the testing and entire cohort, respectively. Multivariate Cox regression displayed that the T category and the risk score of the signature were independent risk factors of colon cancer survival. Also, we constructed an SFs-AS network based on 11 SFs and 48 AS events.

Conclusions: We identified an eleven-AS signature of colon cancer. This signature could be treated as an independent prognostic factor.

Citing Articles

Population-enriched innate immune variants may identify candidate gene targets at the intersection of cancer and cardio-metabolic disease.

Yeyeodu S, Hanafi D, Webb K, Laurie N, Kimbro K Front Endocrinol (Lausanne). 2024; 14:1286979.

PMID: 38577257 PMC: 10991756. DOI: 10.3389/fendo.2023.1286979.


Differential Expression of Lonp1 Isoforms in Cancer Cells.

Zanini G, Selleri V, De Gaetano A, Gibellini L, Malerba M, Mattioli A Cells. 2022; 11(23).

PMID: 36497197 PMC: 9739308. DOI: 10.3390/cells11233940.

References
1.
Zhang Y, Wang Q, Chen L, Yang H . Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells. Mol Cancer Ther. 2015; 14(3):799-809. PMC: 4456303. DOI: 10.1158/1535-7163.MCT-14-0648. View

2.
Chang Y, Su C, Chen M, Chen W, Chen C, Hsiao M . Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promote colon cancer metastasis and is associated with poor prognosis. Mol Cancer. 2017; 16(1):135. PMC: 5547507. DOI: 10.1186/s12943-017-0687-7. View

3.
Edwards B, Ward E, Kohler B, Eheman C, Zauber A, Anderson R . Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2009; 116(3):544-73. PMC: 3619726. DOI: 10.1002/cncr.24760. View

4.
Huang X, Liu J, Mo X, Liu H, Wei C, Huang L . Systematic profiling of alternative splicing events and splicing factors in left- and right-sided colon cancer. Aging (Albany NY). 2019; 11(19):8270-8293. PMC: 6814588. DOI: 10.18632/aging.102319. View

5.
Wang X, Zhang D, Zhang C, Sun Y . Identification of epigenetic methylation-driven signature and risk loci associated with survival for colon cancer. Ann Transl Med. 2020; 8(6):324. PMC: 7186601. DOI: 10.21037/atm.2020.02.94. View